Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T20:59:15.445Z.
Calculation as of: 2026-10-06T20:59:15.445Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f896dd83f1f74da7f4e84885d6bb04cd833df246353afdbeec9bf8c0bdc7d1c4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$261.43M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.56M
EV/EBIT Ratio
N/A
TTM Avg
5.32x
3Y Avg
26.78x
5Y Avg
44.78x
Market Cap
$259.49M
EV/EBIT Ratio
N/A
TTM Avg
2223.35x
3Y Avg
2223.35x
5Y Avg
2223.35x
Market Cap
$259.14M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.12M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$258.63M
EV/EBIT Ratio
N/A
TTM Avg
162862.62x
3Y Avg
112489.16x
5Y Avg
112489.16x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $261.27M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A | 5.32x | 26.78x | 44.78x |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | N/A | 2223.35x | 2223.35x | 2223.35x |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | N/A | 162862.62x | 112489.16x | 112489.16x |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | N/A | 11.31x | 11.31x | 15.93x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
